[
 {
  "trial": "T018",
  "source": "library",
  "arms": {
   "Ketamine group": {
    "randomized": null,
    "analysed": "327"
   },
   "Control group (no injection; PCIA without ketamine)": {
    "randomized": null,
    "analysed": "327"
   }
  },
  "depression": [
   {
    "measure": "EPDS (PPD at 6-8 weeks; postpartum blues at 4-6 days, EPDS > 9)",
    "day": -1,
    "form": "count",
    "definition": "EPDS > 9 (antenatal depressive symptom, gestational weeks 36-40)",
    "location": "Table 1, Antenatal depressive symptom: Yes",
    "values": {
     "Ketamine group": {
      "events": "122",
      "n": null
     },
     "Control group (no injection; PCIA without ketamine)": {
      "events": "116",
      "n": null
     }
    }
   },
   {
    "measure": "EPDS (PPD at 6-8 weeks; postpartum blues at 4-6 days, EPDS > 9)",
    "day": 4,
    "form": "mean_sd",
    "location": "Table 2, 4 days postpartum, EPDS score",
    "values": {
     "Ketamine group": {
      "mean": "4.27",
      "sd": "3.8",
      "n": "327"
     },
     "Control group (no injection; PCIA without ketamine)": {
      "mean": "5.17",
      "sd": "4.6",
      "n": "327"
     }
    }
   },
   {
    "measure": "EPDS (PPD at 6-8 weeks; postpartum blues at 4-6 days, EPDS > 9)",
    "day": 4,
    "form": "count",
    "definition": "EPDS > 9 (prevalence of postpartum blues)",
    "location": "Table 2, 4 days postpartum, Prevalence of postpartum blues",
    "values": {
     "Ketamine group": {
      "events": "39",
      "n": "327"
     },
     "Control group (no injection; PCIA without ketamine)": {
      "events": "60",
      "n": "327"
     }
    }
   },
   {
    "measure": "EPDS (PPD at 6-8 weeks; postpartum blues at 4-6 days, EPDS > 9)",
    "day": 42,
    "form": "mean_sd",
    "location": "Table 2, 42 days postpartum, EPDS score",
    "values": {
     "Ketamine group": {
      "mean": "4.90",
      "sd": "4.3",
      "n": "327"
     },
     "Control group (no injection; PCIA without ketamine)": {
      "mean": "5.55",
      "sd": "5.0",
      "n": "327"
     }
    }
   },
   {
    "measure": "EPDS (PPD at 6-8 weeks; postpartum blues at 4-6 days, EPDS > 9)",
    "day": 42,
    "form": "count",
    "definition": "EPDS > 9 (prevalence of postpartum depression)",
    "location": "Table 2, 42 days postpartum, Prevalence of postpartum depression",
    "values": {
     "Ketamine group": {
      "events": "42",
      "n": "327"
     },
     "Control group (no injection; PCIA without ketamine)": {
      "events": "64",
      "n": "327"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS postoperative pain",
    "day": 1,
    "form": "mean_sd",
    "location": "Results 3.3 Secondary outcomes, text (first postoperative day)",
    "values": {
     "Ketamine group": {
      "mean": "1.85",
      "sd": null,
      "n": null
     },
     "Control group (no injection; PCIA without ketamine)": {
      "mean": "1.77",
      "sd": null,
      "n": null
     }
    }
   },
   {
    "measure": "NRS postoperative pain",
    "day": 2,
    "form": "mean_sd",
    "location": "Results 3.3 Secondary outcomes, text (second postoperative day)",
    "values": {
     "Ketamine group": {
      "mean": "1.20",
      "sd": null,
      "n": null
     },
     "Control group (no injection; PCIA without ketamine)": {
      "mean": "1.22",
      "sd": null,
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Results 3.3 Secondary outcomes, text",
    "values": {
     "Ketamine group": {
      "dizziness": "18",
      "hallucination": "4",
      "visual": "11"
     },
     "Control group (no injection; PCIA without ketamine)": {
      "dizziness": "14"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2014-08",
   "end": "2016-12"
  },
  "registration": {
   "number": "ChiCTR-ROC-17,012,944",
   "date": null
  },
  "note": "Per-arm randomized numbers are not printed: 702 recruited, 654 included (Fig. 1 values not in the text); Table 2 'Number' 327 per arm is used for analysed and n. Days 4 and 42 are as Table 2 labels them (Methods: follow-up at 4-6 days and 6-8 weeks). The day -1 count is antenatal EPDS > 9 at gestational weeks 36-40; Table 1 prints the control value as '116(35,.5)'; its n is not printed. EPDS item-10 suicidal ideation (Table 3) not entered as a depression measure. Pain: only means printed, no SD or n; p = 0.201 (day 1) and 0.673 (day 2). AEs are intraoperative; visual = nystagmus (11, 3.4%). Control: vomiting 30, dizziness 14, and 'No other adverse reactions were observed in the control group' (no printed zeros, so control hallucination and visual left out). Vomiting (62 vs 30) is not a listed category. 'During PCIA time, no obvious adverse reactions were found in both groups.' Enrollment period is from Methods 2.1 (Results give none). Registration printed with commas as given."
 },
 {
  "trial": "T031",
  "source": "fulltext",
  "arms": {
   "Ketamine group": {
    "randomized": "33",
    "analysed": "32"
   },
   "Placebo group": {
    "randomized": "33",
    "analysed": "32"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1, Depression score (EPDS, day before surgery)",
    "values": {
     "Ketamine group": {
      "median": "12",
      "q1": "10",
      "q3": "13",
      "n": "32"
     },
     "Placebo group": {
      "median": "11",
      "q1": "10",
      "q3": "12",
      "n": "32"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3, Depression score at 48 h",
    "values": {
     "Ketamine group": {
      "median": "9",
      "q1": "6",
      "q3": "13",
      "n": "32"
     },
     "Placebo group": {
      "median": "8",
      "q1": "6",
      "q3": "10",
      "n": "32"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 2,
    "form": "change_median_iqr",
    "location": "Table 3, Change from baseline depression score, At 48 h",
    "values": {
     "Ketamine group": {
      "median": "−4",
      "q1": "−5",
      "q3": "0",
      "n": "32"
     },
     "Placebo group": {
      "median": "−2",
      "q1": "−4",
      "q3": "−1",
      "n": "32"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "median_iqr",
    "location": "Table 3, Depression score at 42 days",
    "values": {
     "Ketamine group": {
      "median": "10",
      "q1": "7",
      "q3": "12",
      "n": "32"
     },
     "Placebo group": {
      "median": "9",
      "q1": "7",
      "q3": "11",
      "n": "32"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "count",
    "definition": "EPDS ≥ 10",
    "location": "Table 3, Depression score ≥10 at 42 days",
    "values": {
     "Ketamine group": {
      "events": "18",
      "n": "32"
     },
     "Placebo group": {
      "events": "14",
      "n": "32"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "change_median_iqr",
    "location": "Table 3, Change from baseline depression score, At 42 days",
    "values": {
     "Ketamine group": {
      "median": "−2",
      "q1": "−4",
      "q3": "0",
      "n": "32"
     },
     "Placebo group": {
      "median": "−2",
      "q1": "−5",
      "q3": "−1",
      "n": "32"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3, Numeric rating scale of pain at rest, At 24 h",
    "values": {
     "Ketamine group": {
      "median": "4",
      "q1": "3",
      "q3": "5",
      "n": "32"
     },
     "Placebo group": {
      "median": "4",
      "q1": "3",
      "q3": "4",
      "n": "32"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 5, Intraoperative period",
    "values": {
     "Ketamine group": {
      "hallucination": "1",
      "dizziness": "5",
      "visual": "3"
     },
     "Placebo group": {
      "hallucination": "0",
      "dizziness": "3",
      "visual": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 5, Postoperative period",
    "values": {
     "Ketamine group": {
      "nightmare": "0"
     },
     "Placebo group": {
      "nightmare": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2017-11-23",
   "end": "2018-05-14"
  },
  "registration": {
   "number": "NCT03336541",
   "date": "08/11/2017"
  },
  "note": "Randomized 33 per arm; one per arm withdrew consent; ITT and per-protocol analyses 32 per arm; safety analysis 33 per arm (Table 5 denominators). Baseline is the EPDS screen the day before surgery. Table 3 also gives Hodges-Lehmann median differences and relative risks; Table 4 gives regression estimates. Pain at 4 h, 8 h and 42 days left out (outside the day 1/2 windows). AEs: visual = diplopia; Table 5 'Dissociative symptoms' (10 vs 3) is a composite of hallucination, dizziness, diplopia and hypertonia, so it is not entered as dissociation; somnolence (4 vs 0), sedation (5 vs 0) and hypertonia (1 vs 0) are not listed categories. Registration date printed as 08/11/2017 (day/month order not stated)."
 },
 {
  "trial": "T033",
  "source": "fulltext",
  "arms": {
   "Group L (low dose)": {
    "randomized": null,
    "analysed": "38"
   },
   "Group M (middle dose)": {
    "randomized": null,
    "analysed": "40"
   },
   "Group H (high dose)": {
    "randomized": null,
    "analysed": "39"
   },
   "Group C (control)": {
    "randomized": null,
    "analysed": "39"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postpartum Depression Scale (EPDS)",
    "day": 7,
    "form": "count",
    "definition": "PPD by EPDS (cut-off not stated)",
    "location": "Table 3, Occurrence of PPD, 1 week",
    "values": {
     "Group L (low dose)": {
      "events": "5",
      "n": "38"
     },
     "Group M (middle dose)": {
      "events": "0",
      "n": "40"
     },
     "Group H (high dose)": {
      "events": "0",
      "n": "39"
     },
     "Group C (control)": {
      "events": "12",
      "n": "39"
     }
    }
   },
   {
    "measure": "Edinburgh Postpartum Depression Scale (EPDS)",
    "day": 42,
    "form": "count",
    "definition": "PPD by EPDS (cut-off not stated)",
    "location": "Table 3, Occurrence of PPD, 6 weeks",
    "values": {
     "Group L (low dose)": {
      "events": "7",
      "n": "38"
     },
     "Group M (middle dose)": {
      "events": "2",
      "n": "40"
     },
     "Group H (high dose)": {
      "events": "1",
      "n": "39"
     },
     "Group C (control)": {
      "events": "14",
      "n": "39"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "effective PCIA presses within 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2, Effective press (times)",
    "values": {
     "Group L (low dose)": {
      "mean": "4.1",
      "sd": "0.8",
      "n": "38"
     },
     "Group M (middle dose)": {
      "mean": "2.9",
      "sd": "0.7",
      "n": "40"
     },
     "Group H (high dose)": {
      "mean": "1.6",
      "sd": "0.6",
      "n": "39"
     },
     "Group C (control)": {
      "mean": "5.4",
      "sd": "1.0",
      "n": "39"
     }
    }
   },
   {
    "measure": "total sufentanil consumption within 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2, Consumption of sufentanil (μg)",
    "values": {
     "Group L (low dose)": {
      "mean": "66.8",
      "sd": "5.1",
      "n": "38"
     },
     "Group M (middle dose)": {
      "mean": "63.4",
      "sd": "3.8",
      "n": "40"
     },
     "Group H (high dose)": {
      "mean": "60.6",
      "sd": "1.2",
      "n": "39"
     },
     "Group C (control)": {
      "mean": "72.0",
      "sd": "4.4",
      "n": "39"
     }
    }
   },
   {
    "measure": "rescue tramadol within 48 h",
    "day": 2,
    "form": "count",
    "definition": "rescue analgesia (tramadol 50 mg i.v.) within 48 h",
    "location": "Table 2, Rescue analgesia [n (%)]",
    "values": {
     "Group L (low dose)": {
      "events": "2",
      "n": "38"
     },
     "Group M (middle dose)": {
      "events": "2",
      "n": "40"
     },
     "Group H (high dose)": {
      "events": "1",
      "n": "39"
     },
     "Group C (control)": {
      "events": "9",
      "n": "39"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 3 (recorded within 48 hours after surgery)",
    "values": {
     "Group L (low dose)": {
      "nightmare": "0",
      "visual": "0"
     },
     "Group M (middle dose)": {
      "nightmare": "0",
      "visual": "0"
     },
     "Group H (high dose)": {
      "nightmare": "0",
      "visual": "0"
     },
     "Group C (control)": {
      "nightmare": "0",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-05-02",
   "end": "2021-12-31"
  },
  "registration": {
   "number": "ChiCTR2200060387",
   "date": "April 7, 2021"
  },
  "note": "160 enrolled and randomized to 4 groups (160 envelopes); per-arm randomized numbers not printed. Excluded after allocation: 1 in C, 2 in L, 1 in H; analysed = Table n (L 38, M 40, H 39, C 39). The EPDS cut-off defining PPD is not stated. Group C 1-week PPD printed as 12 (30.1), though 12/39 is 30.8%. Pain measures are totals over the 48 h PCIA period, entered at day 2. AEs within 48 h: nightmares and diplopia (visual) 0 in every group; nausea/vomiting and skin itching are not listed categories. Enrollment period from Methods 2.4. Registration date printed as April 7, 2021, though the ChiCTR number begins 22."
 },
 {
  "trial": "T034",
  "source": "fulltext",
  "arms": {
   "SC group": {
    "randomized": "8",
    "analysed": "8"
   },
   "IV group": {
    "randomized": "8",
    "analysed": "8"
   },
   "Placebo group": {
    "randomized": "7",
    "analysed": "7"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postpartum Depression Scale (EPDS)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1, Pre-operative screening, Depression (EPDS)",
    "values": {
     "SC group": {
      "mean": "6.25",
      "sd": "6.27",
      "n": "8"
     },
     "IV group": {
      "mean": "5",
      "sd": "4.78",
      "n": "8"
     },
     "Placebo group": {
      "mean": "8.29",
      "sd": "4.72",
      "n": "7"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "opioid consumption first 48 h (oral MME)",
    "day": 2,
    "form": "mean_sd",
    "location": "Results, 'Postpartum mood, surgical site pain, opioid consumption, and breastfeeding', text",
    "values": {
     "SC group": {
      "mean": "68.4",
      "sd": null,
      "n": null
     },
     "IV group": {
      "mean": "67.0",
      "sd": null,
      "n": null
     },
     "Placebo group": {
      "mean": "88.6",
      "sd": null,
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 2, Adverse effects",
    "values": {
     "SC group": {
      "any_ae": "6",
      "dizziness": "1",
      "visual": "1",
      "hallucination": "0"
     },
     "IV group": {
      "any_ae": "6",
      "dizziness": "3",
      "visual": "3",
      "hallucination": "0"
     },
     "Placebo group": {
      "any_ae": "7",
      "dizziness": "1",
      "visual": "1",
      "hallucination": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-12",
   "end": "2021-08"
  },
  "registration": {
   "number": "NCT04227704",
   "date": "14/01/2020"
  },
  "note": "No depression numbers after the procedure: EPDS on days 1, 2, 21 and 42 appears only in Fig. 2 (graphs, no printed values); 8 women (34.8%) screened positive (EPDS > 12) on at least one postpartum assessment, not given by arm. Randomized = allocated (8, 8, 7); 25 consented and 2 were withdrawn before receiving the intervention, and the text does not say whether that was after allocation. Baseline EPDS is the pre-operative screen on the day of surgery, mean (SD) per Table 1's footnote. Opioid MME: means only, p = 0.83. Surgical-site pain on days 1 and 2 only in Fig. 2. Table 2 has no window label; taken as intraoperative because its rows match the Methods' list of intraoperative adverse effects and the text calls the shivering difference in it (p = 0.01) intraoperative. any_ae = 'Self-reported AE incidence' (hemodynamic AE incidence separately 3, 3, 2). Dizziness and visual are the 'Mild' rows (moderate and severe rows 0). visual = blurred vision; diplopia separately 0, 1, 1 (SC, IV, placebo; mild). hallucination 0 is from the combined row 'Euphoria, Amnesia, Hallucinations, Nystagmus', printed 0 (0) in each arm. Enrollment period from Methods."
 },
 {
  "trial": "T040",
  "source": "fulltext",
  "arms": {
   "Ketamine group": {
    "randomized": "20",
    "analysed": "20"
   },
   "Placebo (saline) group": {
    "randomized": "20",
    "analysed": "20"
   }
  },
  "depression": [
   {
    "measure": "MADRS",
    "day": -1,
    "form": "mean_sd",
    "location": "Extended Data Table 1, MADRS total score, Day 0 (pre-infusion)",
    "values": {
     "Ketamine group": {
      "mean": "25.1",
      "sd": "8.3",
      "n": "20"
     },
     "Placebo (saline) group": {
      "mean": "29.9",
      "sd": "7.0",
      "n": "19"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1, MADRS total score (screening visit)",
    "values": {
     "Ketamine group": {
      "mean": "27.7",
      "sd": "7.8",
      "n": "20"
     },
     "Placebo (saline) group": {
      "mean": "30.6",
      "sd": "6.3",
      "n": "20"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 1,
    "form": "mean_sd",
    "location": "Extended Data Table 1, MADRS total score, Day 1",
    "values": {
     "Ketamine group": {
      "mean": "12.7",
      "sd": "7.6",
      "n": "20"
     },
     "Placebo (saline) group": {
      "mean": "16.4",
      "sd": "10.0",
      "n": "19"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 1,
    "form": "change_mean_sd",
    "location": "Results, Outcomes, second paragraph (change from day 0 to day 1)",
    "values": {
     "Ketamine group": {
      "mean": "−12.4",
      "sd": "9.2",
      "n": null
     },
     "Placebo (saline) group": {
      "mean": "−14.7",
      "sd": "9.0",
      "n": null
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 2,
    "form": "mean_sd",
    "location": "Extended Data Table 1, MADRS total score, Day 2",
    "values": {
     "Ketamine group": {
      "mean": "15.1",
      "sd": "11.1",
      "n": "19"
     },
     "Placebo (saline) group": {
      "mean": "17.5",
      "sd": "11.5",
      "n": "20"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 3,
    "form": "mean_sd",
    "location": "Extended Data Table 1, MADRS total score, Day 3",
    "values": {
     "Ketamine group": {
      "mean": "17.0",
      "sd": "10.5",
      "n": "19"
     },
     "Placebo (saline) group": {
      "mean": "17.2",
      "sd": "12.0",
      "n": "20"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 5,
    "form": "mean_sd",
    "location": "Extended Data Table 1, MADRS total score, Day 5",
    "values": {
     "Ketamine group": {
      "mean": "16.9",
      "sd": "8.0",
      "n": "19"
     },
     "Placebo (saline) group": {
      "mean": "16.9",
      "sd": "10.1",
      "n": "18"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 7,
    "form": "mean_sd",
    "location": "Extended Data Table 1, MADRS total score, Day 7",
    "values": {
     "Ketamine group": {
      "mean": "15.9",
      "sd": "9.2",
      "n": "18"
     },
     "Placebo (saline) group": {
      "mean": "18.5",
      "sd": "10.8",
      "n": "19"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 14,
    "form": "mean_sd",
    "location": "Extended Data Table 1, MADRS total score, Day 14",
    "values": {
     "Ketamine group": {
      "mean": "16.9",
      "sd": "10.0",
      "n": "19"
     },
     "Placebo (saline) group": {
      "mean": "16.2",
      "sd": "12.5",
      "n": "19"
     }
    }
   },
   {
    "measure": "HADS score",
    "day": -1,
    "form": "mean_sd",
    "location": "Extended Data Table 1, HADS total score, Day 0 (pre-infusion)",
    "values": {
     "Ketamine group": {
      "mean": "22.9",
      "sd": "4.2",
      "n": "20"
     },
     "Placebo (saline) group": {
      "mean": "24.6",
      "sd": "5.6",
      "n": "19"
     }
    }
   },
   {
    "measure": "HADS score",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1, HADS Total score (screening visit)",
    "values": {
     "Ketamine group": {
      "mean": "24.6",
      "sd": "6.0",
      "n": "20"
     },
     "Placebo (saline) group": {
      "mean": "24.7",
      "sd": "5.7",
      "n": "20"
     }
    }
   },
   {
    "measure": "HADS score",
    "day": 1,
    "form": "mean_sd",
    "location": "Extended Data Table 1, HADS total score, Day 1",
    "values": {
     "Ketamine group": {
      "mean": "17.8",
      "sd": "6.6",
      "n": "20"
     },
     "Placebo (saline) group": {
      "mean": "19.9",
      "sd": "5.5",
      "n": "19"
     }
    }
   },
   {
    "measure": "HADS score",
    "day": 2,
    "form": "mean_sd",
    "location": "Extended Data Table 1, HADS total score, Day 2",
    "values": {
     "Ketamine group": {
      "mean": "18.8",
      "sd": "7.5",
      "n": "18"
     },
     "Placebo (saline) group": {
      "mean": "21.2",
      "sd": "5.9",
      "n": "20"
     }
    }
   },
   {
    "measure": "HADS score",
    "day": 3,
    "form": "mean_sd",
    "location": "Extended Data Table 1, HADS total score, Day 3",
    "values": {
     "Ketamine group": {
      "mean": "19.3",
      "sd": "6.3",
      "n": "19"
     },
     "Placebo (saline) group": {
      "mean": "20.8",
      "sd": "5.4",
      "n": "20"
     }
    }
   },
   {
    "measure": "HADS score",
    "day": 5,
    "form": "mean_sd",
    "location": "Extended Data Table 1, HADS total score, Day 5",
    "values": {
     "Ketamine group": {
      "mean": "18.3",
      "sd": "4.8",
      "n": "19"
     },
     "Placebo (saline) group": {
      "mean": "18.9",
      "sd": "7.3",
      "n": "19"
     }
    }
   },
   {
    "measure": "HADS score",
    "day": 7,
    "form": "mean_sd",
    "location": "Extended Data Table 1, HADS total score, Day 7",
    "values": {
     "Ketamine group": {
      "mean": "18.4",
      "sd": "5.3",
      "n": "16"
     },
     "Placebo (saline) group": {
      "mean": "19.6",
      "sd": "8.1",
      "n": "19"
     }
    }
   },
   {
    "measure": "HADS score",
    "day": 14,
    "form": "mean_sd",
    "location": "Extended Data Table 1, HADS total score, Day 14",
    "values": {
     "Ketamine group": {
      "mean": "16.4",
      "sd": "7.2",
      "n": "19"
     },
     "Placebo (saline) group": {
      "mean": "17.2",
      "sd": "8.5",
      "n": "19"
     }
    }
   },
   {
    "measure": "HADS depression subscore",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1, HADS Depression subscore (screening visit)",
    "values": {
     "Ketamine group": {
      "mean": "12.0",
      "sd": "3.2",
      "n": "20"
     },
     "Placebo (saline) group": {
      "mean": "10.5",
      "sd": "3.6",
      "n": "20"
     }
    }
   },
   {
    "measure": "PHQ-8 total score",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1, PHQ-8 total score (screening)",
    "values": {
     "Ketamine group": {
      "mean": "15.8",
      "sd": "3.6",
      "n": "20"
     },
     "Placebo (saline) group": {
      "mean": "15.8",
      "sd": "3.8",
      "n": "20"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "cumulative and daily opioid use (MME)",
    "day": 1,
    "form": "mean_sd",
    "location": "Extended Data Table 2, Average Daily Inpatient Opioid Use (MME), Day 1",
    "values": {
     "Ketamine group": {
      "mean": "81.6",
      "sd": "59.6",
      "n": "14"
     },
     "Placebo (saline) group": {
      "mean": "69.2",
      "sd": "62.2",
      "n": "16"
     }
    }
   },
   {
    "measure": "cumulative and daily opioid use (MME)",
    "day": 2,
    "form": "mean_sd",
    "location": "Extended Data Table 2, Average Daily Inpatient Opioid Use (MME), Day 2",
    "values": {
     "Ketamine group": {
      "mean": "83.3",
      "sd": "65.2",
      "n": "8"
     },
     "Placebo (saline) group": {
      "mean": "77.6",
      "sd": "71.3",
      "n": "13"
     }
    }
   }
  ],
  "adverse_events": [],
  "blinding_check": {
   "who": "participants",
   "day": 14,
   "values": null,
   "location": "Results, Outcomes, fourth paragraph; Figure 2B; Extended Data Figure 1",
   "summary": "Guesses by arm appear only in Figure 2B as percentages of each group (n=19 per group), with no printed values. Text: 36.8% of all participants guessed correctly; Cohen's kappa = 0.33. Guesses pooled across arms: 'ketamine' n=16, 'placebo' n=10, 'I don't know' n=12 (Extended Data Figure 1 caption: 17, 10, 11)."
  },
  "enrollment": {
   "start": "2020-02-19",
   "end": "2022-08-18"
  },
  "registration": null,
  "note": "Randomized 20 per arm; ITT n=20 per arm. Days are post-infusion days (infusion during surgery). Two day -1 entries each for MADRS and HADS: the first is the pre-infusion baseline on the day of surgery (Extended Data Table 1 'Day 0'), the second the screening visit (Table 1; on average 5 days before surgery). HADS depression subscore and PHQ-8 were reported only at screening. Extended Data Table 1 also gives MADRS response (>=50% reduction from screening) and remission (MADRS <=12) as n/N by day; not entered as counts since they count improvement, not depression. Pain: BPI-SF only at screening and day 14 (average pain 4.8 [SD 1.5] vs 3.7 [SD 2.0]); cumulative opioid only in Fig. 2E. Opioid entries are average daily inpatient MME; n counts only patients hospitalized the whole day. No psychotomimetic AEs reported (one death in the ketamine group 5 days post-infusion, one reoperation in the placebo group). No registration number in the source."
 },
 {
  "trial": "T064",
  "source": "fulltext",
  "arms": {
   "Ketamine": {
    "randomized": "152",
    "analysed": "129"
   },
   "Placebo (0.9% saline)": {
    "randomized": "149",
    "analysed": "132"
   }
  },
  "depression": [
   {
    "measure": "HADS depression score (>= 8)",
    "day": -1,
    "form": "count",
    "definition": "HADS Depression score of 8 or above",
    "location": "Table 1, Symptoms of depression (denominators from footnote ††)",
    "values": {
     "Ketamine": {
      "events": "21",
      "n": "136"
     },
     "Placebo (0.9% saline)": {
      "events": "28",
      "n": "132"
     }
    }
   },
   {
    "measure": "HADS depression score (>= 8)",
    "day": 7,
    "form": "count",
    "definition": "HADS Depression score of 8 or above",
    "location": "Table 2, Seven days following surgery, Symptoms of depression (denominators from footnote ***)",
    "values": {
     "Ketamine": {
      "events": "19",
      "n": "124"
     },
     "Placebo (0.9% saline)": {
      "events": "27",
      "n": "128"
     }
    }
   },
   {
    "measure": "HADS depression score (>= 8)",
    "day": 90,
    "form": "count",
    "definition": "HADS Depression score of 8 or above",
    "location": "Table 2, Ninety days following surgery, Symptoms of depression (denominators from footnote ††)",
    "values": {
     "Ketamine": {
      "events": "11",
      "n": "124"
     },
     "Placebo (0.9% saline)": {
      "events": "24",
      "n": "113"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "overall",
    "location": "Results, Safety (perioperative adverse events)",
    "values": {
     "Ketamine": {
      "any_ae": "33"
     },
     "Placebo (0.9% saline)": {
      "any_ae": "34"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Results, Safety (postoperative psychiatric adverse events, first seven days)",
    "values": {
     "Ketamine": {
      "psychiatric_any": "4"
     },
     "Placebo (0.9% saline)": {
      "psychiatric_any": "5"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2017-03-20",
   "end": "2019-05-28"
  },
  "registration": {
   "number": "NCT02892916",
   "date": "September 2016"
  },
  "note": "Randomized 152 vs 149 (abstract); 9 withdrew consent; ITT 149 vs 143 (Table headers); mITT 129 vs 132, on which all analyses were run, entered as analysed. Table 2 ORs: day 7 0.71 [0.30-1.70], day 90 0.34 [0.13-0.86]. VAS, opioid requirements and DN4 are only in supplementary Tables S6-S7, not in the source. AEs: perioperative adverse events 33 [23.1%] ketamine vs 34 [23.4%] placebo (window entered as overall); postoperative psychiatric adverse events to day 7, 4 of 149 vs 5 of 143 (visual and auditory hallucinations collected, nightmares not). Registered September 2016; the outcome change was registered in May 2019."
 },
 {
  "trial": "T073",
  "source": "registry",
  "arms": {
   "Epidural morphine 3 mg + IV saline": {
    "randomized": "26",
    "analysed": null
   },
   "Epidural morphine 3 mg + IV ketamine 0.3 mg/kg": {
    "randomized": "26",
    "analysed": null
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postnatal Depression Scale (presence of postpartum depression)",
    "day": 7,
    "form": "mean_range",
    "location": "Registry outcome: Presence of Postpartum Depression, 1 week after delivery",
    "values": {
     "Epidural morphine 3 mg + IV saline": {
      "mean": "7.0",
      "min": "4.7",
      "max": "9.4",
      "n": "19"
     },
     "Epidural morphine 3 mg + IV ketamine 0.3 mg/kg": {
      "mean": "6.7",
      "min": "4.9",
      "max": "9.4",
      "n": "24"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (presence of postpartum depression)",
    "day": 42,
    "form": "mean_range",
    "location": "Registry outcome: Presence of Postpartum Depression, 6 weeks after delivery",
    "values": {
     "Epidural morphine 3 mg + IV saline": {
      "mean": "4.7",
      "min": "2.8",
      "max": "6.6",
      "n": "19"
     },
     "Epidural morphine 3 mg + IV ketamine 0.3 mg/kg": {
      "mean": "4.8",
      "min": "3.3",
      "max": "6.3",
      "n": "22"
     }
    }
   },
   {
    "measure": "PROMIS-29 depressive symptoms",
    "day": 90,
    "form": "mean_range",
    "location": "Registry outcome: Promis 29 Profile (Depressive Symptoms Question Only), 3 month",
    "values": {
     "Epidural morphine 3 mg + IV saline": {
      "mean": "43",
      "min": "40.9",
      "max": "45.2",
      "n": "20"
     },
     "Epidural morphine 3 mg + IV ketamine 0.3 mg/kg": {
      "mean": "43.6",
      "min": "41.2",
      "max": "45.9",
      "n": "21"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "McGill Pain Questionnaire (perineal pain)",
    "day": 1,
    "form": "mean_range",
    "location": "Registry outcome: Perineal Pain (McGill Pain Questionnaire), Day 1 after delivery",
    "values": {
     "Epidural morphine 3 mg + IV saline": {
      "mean": "10.4",
      "min": "7.9",
      "max": "12.9",
      "n": "23"
     },
     "Epidural morphine 3 mg + IV ketamine 0.3 mg/kg": {
      "mean": "12.9",
      "min": "10.0",
      "max": "15.8",
      "n": "24"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Registry adverse events (48 hours after delivery)",
    "values": {
     "Epidural morphine 3 mg + IV saline": {
      "any_ae": "14"
     },
     "Epidural morphine 3 mg + IV ketamine 0.3 mg/kg": {
      "any_ae": "13"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "NCT03470675",
   "date": null
  },
  "note": "Registry results. Registry arm names differ only in capitals ('Epidural Morphine 3 mg + IV Saline', 'Epidural Morphine 3 mg + IV Ketamine 0.3 mg/kg'); the 'Epidural saline + IV saline' arm (role other) is left out. Randomized = participant flow STARTED (26, 26); analysed differs by outcome, so null, and each entry's n is the registry's 'Analysed'. The registry labels the dispersion of these outcomes 'MEAN Full Range' (lowerLimit, upperLimit), entered as mean_range with the limits as min and max; the limits are non-integer for the integer-scored EPDS, so they may be confidence intervals mislabeled. The primary VRS outcome is labeled 'MEAN Inter-Quartile Range'. Pain at 1 week, 6 weeks, 3 months and 1 year left out (outside day 1/2). AEs over 48 h after delivery: serious 0/26 vs 0/25; any_ae = 'other' AEs, 14/26 vs 13/25 (AE denominators 26 and 25); none psychotomimetic. No enrollment dates in the source."
 },
 {
  "trial": "T086",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": null,
    "analysed": "140"
   },
   "Control group": {
    "randomized": null,
    "analysed": "140"
   }
  },
  "depression": [
   {
    "measure": "EPDS (postpartum depression incidence, >= 10)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1, Pre-operative EPDS score",
    "values": {
     "Esketamine group": {
      "mean": "8.9",
      "sd": "4.0",
      "n": "140"
     },
     "Control group": {
      "mean": "9.3",
      "sd": "4.0",
      "n": "140"
     }
    }
   },
   {
    "measure": "EPDS (postpartum depression incidence, >= 10)",
    "day": -1,
    "form": "count",
    "definition": "Prenatal depression (Table 1 label; criterion not stated)",
    "location": "Table 1, Prenatal depression",
    "values": {
     "Esketamine group": {
      "events": "57",
      "n": "140"
     },
     "Control group": {
      "events": "64",
      "n": "140"
     }
    }
   },
   {
    "measure": "Self-Rating Depression Scale (SDS)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1, Pre-operative SDS score",
    "values": {
     "Esketamine group": {
      "mean": "45.8",
      "sd": "9.0",
      "n": "140"
     },
     "Control group": {
      "mean": "45.7",
      "sd": "10.1",
      "n": "140"
     }
    }
   },
   {
    "measure": "EPDS (postpartum depression incidence, >= 10)",
    "day": null,
    "form": "count",
    "definition": "EPDS ≥10",
    "location": "Table 2, PPD (total)",
    "values": {
     "Esketamine group": {
      "events": "41",
      "n": "140"
     },
     "Control group": {
      "events": "50",
      "n": "140"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 4, Intra-operative",
    "values": {
     "Esketamine group": {
      "dizziness": "4",
      "hallucination": "2",
      "nightmare": "5"
     },
     "Control group": {
      "dizziness": "0",
      "hallucination": "0",
      "nightmare": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 4, Post-operative",
    "values": {
     "Esketamine group": {
      "dizziness": "1"
     },
     "Control group": {
      "dizziness": "4"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2022-01-15",
   "end": "2022-07-30"
  },
  "registration": {
   "number": "ChiCTR2100050976",
   "date": "09/09/2021"
  },
  "note": "The source never says when the postoperative EPDS was given (the sample size cites a 3rd-day PPD incidence from another study), so the PPD entry's day is null. PPD = EPDS ≥10. 290 recruited; 10 excluded (2 converted to general anaesthesia, 1 haemorrhage, 5 lost to follow-up, 2 L-scale >60); per-arm randomized not printed; analysed 140 per arm. Day -1 entries are from the day before surgery. Table 2 also gives PPD by personality type. Pain NRS only in Fig. 2 (no printed values); indomethacin use not reported. Drowsiness, nausea/vomiting and RSS >3 sedation counts are not listed AE categories. Enrollment period from Methods."
 },
 {
  "trial": "T108",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": null,
    "analysed": "35"
   },
   "Control group": {
    "randomized": null,
    "analysed": "34"
   }
  },
  "depression": [
   {
    "measure": "HAMD-17",
    "day": -1,
    "form": "count",
    "definition": "HAMD-17 > 7",
    "location": "Table 2, Pre-operation, Yes",
    "values": {
     "Esketamine group": {
      "events": "10",
      "n": "35"
     },
     "Control group": {
      "events": "6",
      "n": "34"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 1,
    "form": "count",
    "definition": "HAMD-17 > 7",
    "location": "Table 2, POD 1, Yes",
    "values": {
     "Esketamine group": {
      "events": "18",
      "n": "35"
     },
     "Control group": {
      "events": "18",
      "n": "34"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 1,
    "form": "change_median_iqr",
    "location": "Table 3, POD 1 (postoperative minus preoperative score)",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "1",
      "q3": "5",
      "n": "35"
     },
     "Control group": {
      "median": "3.5",
      "q1": "1",
      "q3": "6.25",
      "n": "34"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 3,
    "form": "count",
    "definition": "HAMD-17 > 7",
    "location": "Table 2, POD 3, Yes",
    "values": {
     "Esketamine group": {
      "events": "15",
      "n": "35"
     },
     "Control group": {
      "events": "16",
      "n": "34"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 3,
    "form": "change_median_iqr",
    "location": "Table 3, POD 3 (postoperative minus preoperative score)",
    "values": {
     "Esketamine group": {
      "median": "1",
      "q1": "0",
      "q3": "3",
      "n": "35"
     },
     "Control group": {
      "median": "2",
      "q1": "1",
      "q3": "5",
      "n": "34"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 5,
    "form": "count",
    "definition": "HAMD-17 > 7",
    "location": "Table 2, POD 5, Yes",
    "values": {
     "Esketamine group": {
      "events": "12",
      "n": "35"
     },
     "Control group": {
      "events": "11",
      "n": "34"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 5,
    "form": "change_median_iqr",
    "location": "Table 3, POD 5 (postoperative minus preoperative score)",
    "values": {
     "Esketamine group": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": "35"
     },
     "Control group": {
      "median": "1",
      "q1": "0",
      "q3": "2",
      "n": "34"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS pain",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 4, POD 1",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "4",
      "n": "35"
     },
     "Control group": {
      "median": "4",
      "q1": "3",
      "q3": "5",
      "n": "34"
     }
    }
   },
   {
    "measure": "VAS pain",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4, POD 2",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "35"
     },
     "Control group": {
      "median": "3",
      "q1": "2",
      "q3": "4",
      "n": "34"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 5",
    "values": {
     "Esketamine group": {
      "dizziness": "4",
      "nightmare": "0",
      "dissociation": "0"
     },
     "Control group": {
      "dizziness": "1",
      "nightmare": "0",
      "dissociation": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-01",
   "end": "2024-12"
  },
  "registration": {
   "number": "ChiCTR2200066303",
   "date": "2022–11–30"
  },
  "note": "80 randomized (per-arm numbers not printed); 11 excluded after randomization; analysed 34 control, 35 esketamine. Depression = HAMD-17 > 7. Table 3 changes are postoperative minus preoperative score, median (IQR). HAMD-17 scores themselves are not in the main text (Supplementary Table 2). VAS at PACU admission, POD 3 and POD 5 left out. Total postoperative opioid (morphine equivalents, mg; 114.9 ± 23.32 control vs 100.9 ± 25.72 esketamine) and PCIA presses (9.32 ± 6.48 vs 6.54 ± 4.39) cover the whole PCIA period (over 72 h), not day 1 or 2, so left out. Enrollment period from Methods."
 }
]